Listerine-maker Kenvue beats estimates on strong essential health product sales

​Investor expectations from the consumer health company, which Johnson & Johnson spun off last year, have been low due to weak uptake for its self-care and skin health products. Its essential health business, however, has been a bright spot.
  • Updated On Aug 6, 2024 at 05:11 PM IST
Read by: 100 Industry Professionals
Reader Image Read by 100 Industry Professionals
London: Kenvue beat Wall Street estimates for second-quarter profit and revenue on Tuesday, helped primarily by better-than-expected sales in its essential health products unit that sells brands including Band-Aid, Listerine and Carefree.

Shares of the company rose 4.7 per cent to $19.05 in premarket trading.

Investor expectations from the consumer health company, which Johnson & Johnson spun off last year, have been low due to weak uptake for its self-care and skin health products. Its essential health business, however, has been a bright spot.

The essential health unit recorded $1.26 billion in revenue for the second quarter, up nearly 5 per cent from a year earlier and above analysts' average estimate of $1.24 billion, according to LSEG data.

Advt
Essential health's adjusted operating income jumped nearly 44 per cent to $359 million, while other segments declined.

Kenvue's skin health business, which sells brands such as Neutrogena and Clean & Clear, was the worst performer, recording a nearly 4 per cent decline in sales to $1.10 billion, compared with LSEG estimate of $1.16 billion.

Sales from self-care - its largest segment that houses Benadryl and Tylenol - slipped 1.6 per cent to $1.64 billion. Analysts, on average, had expected $1.60 billion.

Kenvue has been focusing on improving sales of its skin health products through increased marketing spend and in-store presence, among other measures.

It raised the marketing spend for this year to up to $400 million from $300 million previously. It's the second time it lifted the forecast, after a 15 per cent jump in February.

The New Jersey-based company posted total second-quarter revenue of $4 billion, above LSEG estimates of $3.94 billion.

On an adjusted basis, Kenvue posted a profit of 32 cents per share, beating analysts' estimates by 4 cents.

The company maintained its adjusted profit forecast for the year at between $1.10 and $1.20 per share. (Reporting by Sneha S K and Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)
  • Published On Aug 6, 2024 at 05:05 PM IST
Be the first one to comment.
Comment Now

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles
Scan to download App